Notice of Ordering Period Extension-Clinical Evaluation of Phenserine Tartrate Extended Controlled Release Tablet

INTRODUCTION PURSUANT TO RFO SUBPART 5.101- PRESOLICITATION NOTICE, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A MODIFICATION UNDER CONTRACT NO. 75N95024D00002 WITH THE UNIVERSITY OF EXETER, UNITED KINGDOM, TO EXTEND THE ORDERING PERIOD BY ONE (1) YEAR. The National Institute on Aging (NIA) intends to modify the single-award Indefinite Quantity Indefinite Delivery (IDIQ) contract no. 75N95024D00002, Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer�s disease and mild to moderate traumatic brain injury. This modification will extend the ordering period as denoted in IDIQ contract clause FAR 52.216-18, Ordering (AUG 2020), to be extended from August 1, 2026, to August 1, 2027. The extension of the IDIQ ordering period will allow for work, especially initially planned task orders 2 and 3 of the IDIQ Statement of Work to be completed. There are no anticipated follow-on procureme…

Excerpt as published. The complete description, attachments, and any amendments are on the official notice.